The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia

Leuk Lymphoma. 2021 Oct;62(10):2531-2534. doi: 10.1080/10428194.2021.1919666. Epub 2021 Apr 26.

Authors

Matthew J Rees¹, Simon Wu², Mridula Mokoonlall³, Caroline H K Dix⁴, Christian E Bryant⁴, James D'Rozario³, Anthony Schwarer^{1

2}, Andrew Grigg¹, Ing Soo Tiong¹

Affiliations

¹ Department of Clinical Haematology, Austin Health, Melbourne, Australia.
² Department of Clinical Haematology, Eastern Health, Melbourne, Australia.
³ Department of Clinical Haematology, Canberra Hospital, Canberra, Australia.
⁴ Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.

PMID: 33899667
DOI: 10.1080/10428194.2021.1919666

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Adult
Antineoplastic Agents* / therapeutic use
Asparaginase / adverse effects
Humans
Middle Aged
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Antineoplastic Agents
Asparaginase